AIM To present the current state-of-the art of molecular imaging in the management of patients affected by inflammatory bowel disease(IBD).METHODS A systematic review of the literature was performed in order to find i...AIM To present the current state-of-the art of molecular imaging in the management of patients affected by inflammatory bowel disease(IBD).METHODS A systematic review of the literature was performed in order to find important original articles on the role of molecular imaging in the management of patients affected by IBD. The search was updated until February 2016 and limited to articles in English.RESULTS Fifty-five original articles were included in this review, highlighting the role of single photon emission tomography and positron emission tomography. CONCLUSION To date, molecular imaging represents a useful tool to detect active disease in IBD. However, the available data need to be validated in prospective multicenter studies on larger patient samples.展开更多
The aim of this study was to collect the evidence on the performance of 2-deoxy-2-[^(18)F]fluoro-D-glucose(^(18)F-FDG)Positron Emission Tomography/Computed Tomography(PET/CT)in terms of detection rate(DR)and diagnosti...The aim of this study was to collect the evidence on the performance of 2-deoxy-2-[^(18)F]fluoro-D-glucose(^(18)F-FDG)Positron Emission Tomography/Computed Tomography(PET/CT)in terms of detection rate(DR)and diagnostic accuracy in identifying hematogenous metastases in patients with differentiated thyroid cancer and compare its performance with that of other imaging techniques.A comprehensive PubMed/MEDLINE database research was carried out to retrieve studies documenting the performance of^(18)F-FDG PET/CT in depicting hematogenous metastases in patients with differentiated thyroid cancer.Statistical analysis was performed on a per-patient and per-lesion basis.The literature search yielded 15 articles to be included in the systematic review.^(18)F-FDG PET/CT showed a pooled DR of 85.08%on a per-patient analysis and 89.70%on a per-lesion analysis.For bone lesions,a high DR(81.78%)was found for^(18)F-FDG PET/CT.For the sub-group analysis of lung lesions,pooled DR was 92.77%for^(18)F-FDG PET/CT,95.02%for CT,and 64.93%for magnetic resonance imaging(MRI).On a per-patient analysis,^(18)F-FDG PET/CT demonstrated a pooled sensitivity(SS)of 87.3%[95%confidence interval(CI):77.3%-94%]and a pooled specificity(SP)of 95.6%(95%CI:87.6-99.1).On a per-lesion analysis(328 metastases),PET/CT showed a pooled SS and SP of 86.3%(95%CI:73.5%-93.5%)and 93.4%(95%CI:71.7%-98.8%)in the detection of hematogenous metastases.The presented systematic review and meta-analysis favor the use of^(18)F-FDG PET/CT in the detection of hematogenous metastases in patients with differentiated thyroid cancer.The limited literature warrants further studies to confirm our findings.展开更多
文摘AIM To present the current state-of-the art of molecular imaging in the management of patients affected by inflammatory bowel disease(IBD).METHODS A systematic review of the literature was performed in order to find important original articles on the role of molecular imaging in the management of patients affected by IBD. The search was updated until February 2016 and limited to articles in English.RESULTS Fifty-five original articles were included in this review, highlighting the role of single photon emission tomography and positron emission tomography. CONCLUSION To date, molecular imaging represents a useful tool to detect active disease in IBD. However, the available data need to be validated in prospective multicenter studies on larger patient samples.
文摘The aim of this study was to collect the evidence on the performance of 2-deoxy-2-[^(18)F]fluoro-D-glucose(^(18)F-FDG)Positron Emission Tomography/Computed Tomography(PET/CT)in terms of detection rate(DR)and diagnostic accuracy in identifying hematogenous metastases in patients with differentiated thyroid cancer and compare its performance with that of other imaging techniques.A comprehensive PubMed/MEDLINE database research was carried out to retrieve studies documenting the performance of^(18)F-FDG PET/CT in depicting hematogenous metastases in patients with differentiated thyroid cancer.Statistical analysis was performed on a per-patient and per-lesion basis.The literature search yielded 15 articles to be included in the systematic review.^(18)F-FDG PET/CT showed a pooled DR of 85.08%on a per-patient analysis and 89.70%on a per-lesion analysis.For bone lesions,a high DR(81.78%)was found for^(18)F-FDG PET/CT.For the sub-group analysis of lung lesions,pooled DR was 92.77%for^(18)F-FDG PET/CT,95.02%for CT,and 64.93%for magnetic resonance imaging(MRI).On a per-patient analysis,^(18)F-FDG PET/CT demonstrated a pooled sensitivity(SS)of 87.3%[95%confidence interval(CI):77.3%-94%]and a pooled specificity(SP)of 95.6%(95%CI:87.6-99.1).On a per-lesion analysis(328 metastases),PET/CT showed a pooled SS and SP of 86.3%(95%CI:73.5%-93.5%)and 93.4%(95%CI:71.7%-98.8%)in the detection of hematogenous metastases.The presented systematic review and meta-analysis favor the use of^(18)F-FDG PET/CT in the detection of hematogenous metastases in patients with differentiated thyroid cancer.The limited literature warrants further studies to confirm our findings.
